poor precision in the reconstruction of diastolic and mean BP and was extremely inaccurate when evaluating systolic BP. Diabetes mellitus, peripheral neuropathy, and increase in systolic BAP significantly predicted the disagreement in systolic pressure measurement between NAP and MAP, F (3.34) = 10.787, p < 0.005, R 2 = 0.488. Conclusion: The Nexfin does not meet the criteria of interchangeability with oscillometric method in our hemodialysis patients. The negative influence of diabetes, neuropathy, and increase of systolic BAP on the reconstruction of systemic systolic pressure raises concerns about the feasibility of Nexfin in patients with a high prevalence of vasculopathy.
Introduction
The Nexfin monitor (BMEYE, Amsterdam, the Netherlands) is a device used for continuous and noninvasive measurement of arterial blood pressure (BP) and cardiac output based on finger arterial pressure pulse contour analysis [1] [2] [3] [4] .
The device was developed on the model of the Finapres [5] , a noninvasive tool used for monitoring systemic BP through direct measurement of finger arterial pressure. The application of this type of finger-cuff technology gives a rather poor estimation of brachial arterial pressure (BAP) since peripheral arteries are more prone to changes in vascular tone and in blood flow than aorta and its branches.
On the contrary, the Nexfin reconstructs BAP from finger arterial pressure by the implementation of cuff-finger technology, which relies on the application of a physiological model and a regression-based level correction to the peripheral changes of systolic and diastolic wave reflections [2] [3] [4] .
Multiple studies showed that reconstructed systemic BP values are comparable to BP values measured by either noninvasive [6] and invasive [7, 8] methods. In particular, Schattenkerk et al. [6] validated the device against the classical auscultatory method (Riva-Rocci/Korotkoff) using the sphygmomanometer. The authors stated that Nexfin reconstructs brachial pressure within the criteria developed by Association for the Advancement of Medical Instrumentation (accuracy, <5 mm Hg and precision, <8 mm Hg between the 2 techniques) [9] with good within-subject precision.
On the basis of this scientific background, the aim of this study was to test the ability of the Nexfin device to reconstruct BAP in maintenance hemodialysis patients. Nevertheless, the validation of Nexfin was outside the scope of our investigation and this study has to be considered a proof of concept. Hence, we studied the level of agreement between BP measurements obtained by the Nexfin and oscillometric devices, when the 2 types of BP readings were analyzed before starting hemodialysis treatment in the same patient and on the same arm.
Methods

Subjects
Forty maintenance hemodialysis patients (27 males) were included in this study. The sample size population was determined on a random basis and no power analysis was performed before enrollment.
Scleroderma, cardiac arrhythmia, positive history of previous vascular surgeries (e.g., vascular access placement, major trauma) on both upper arms, and previous or current documentation of central vein obstruction (vein thrombosis or stenosis) were the criteria on which patients were excluded from this study.
All participants were outpatients and were in a stable clinical condition; they received thrice-weekly intermittent hemodialysis treatments at the Dialysis Unit of our hospital. The most common vascular access for hemodialysis was native arteriovenous fistula (AVF; 80%) followed by tunneled central venous catheter (CVC) placed in the internal jugular vein (20%).
Radiological examinations of chest and/or abdomen were reviewed in order to identify the presence of calcifications in large vessels of each patient. Vascular calcification was detected by analyzing plain X-rays and CT images. Because the assessment of vascular calcification was not routinely performed in our patients, calcifying arterial disease was mainly an incidental finding. Vascular calcification was evaluated from the level of aortic arch to iliac bifurcation. Diagnosis of vascular calcification was made when at least one aortic segment (aortic arch, thoracic, and abdominal aorta) exhibited calcified deposits within the vessel wall. No attempt was made to quantify the extension and the severity of the calcified lesions.
Measurements
All BP measurements were performed on the non-AVF arm; in patients with CVC, BP was recorded on the opposite site of the central line. BAP spanned the range from hypotension (96 mm Hg systolic and 39 mm Hg diastolic) to hypertension (158 mm Hg systolic and 80 mm Hg diastolic).
Finger arterial measurements were performed with the Nexfin monitor through an appropriately sized finger cuff, applied around the mid-phalanx of the middle finger.
The measurement method builds on the volume-clamp method invented by the Czech physiologist Jan Peñáz [10, 11] . Technically, a controlled pneumatic cuff system placed around the finger clamps the artery to a constant volume by applying a varying counter pressure equivalent to the arterial pressure using a built-in photoelectric plethysmograph.
The determination of a transmural pressure across the finger arterial walls equaling zero allows an indirect measure of intraarterial pressure. A built-in system for physiological calibration (Physiocal), developed by Wesseling et al. [12] , guarantees the "unloaded" diameter of the finger artery, compensating for any changes in the vasomotor tone. Using a population-based formula, Nexfin reconstructs BAP from peripheral BP waveform transformation in order to compensate the BP drop due to resistance to flow in arterioles [7, 13] .
The device is also equipped with a "heart reference system" with 2 sensors placed respectively at the finger and at the right atrial level to compensate for any possible difference in hydrosta tic pressure between the heart and the finger.
BAP was measured by BP monitor (Fresenius 5008TM monitor, Fresenius Medical Care, Bad Homburg, Germany), an automated oscillometric sphygmomanometer, applying a cuff around the upper arm.
The mercury sphygmomanometer device, although was the "gold standard" for office BP measurement, was not used in this study because it has been removed from clinical practice due to environmental concerns related to the contamination caused by mercury [14] [15] [16] .
BAP was estimated based on the international guidelines for office BP measurement [14, 17] .
Measurements were performed before starting hemodialysis by a trained physician and a dialysis nurse. Patients were made to lie down in a supine position on their dialysis bed in a quiet and temperature-controlled room. The first BP reading was taken after at least 5 min of rest; patients were refrained from speaking or moving when measurements were being recorded. Nexfin measurement was performed first in order to avoid the influence of transient increase in blood flow that occurs following a brief period of ischemia [18] after cuff inflation with sphygmomanometer. Soon after the stabilization of the arterial wave on the Nexfin monitor, the trace was recorded for 1 min to obtain a more accurate average of systolic and diastolic Nexfix arterial pressure (NAP).
BAP measurements were provided on the same arm and within a short time following the application of Nexfin to limit the magnitude of spontaneous variations in BP.
A series of 3 BP determinations were taken at intervals of at least 1 min between readings; systolic and diastolic BAP measurements were the results of the average of 3 single recordings.
For both the techniques, the mean arterial pressure (MAP) was calculated with the same formula: 1/3 * (SBP-DBP) + DBP to avoid bias by using different formulas.
Statistical Analysis
Results are presented as mean ± SD unless otherwise stated. Continuous and normally distributed data ( Fig. 1 ) were compared using Student t test. Results were considered significant when the p value was <0.05. Paired BP measurements were compared using the Bland-Altman method [19] , that evaluates the agreement that exists within repeated measures between the 2 measurement devices. The values of each pair of NAP and BAP were averaged and their differences (BAP -NA) were computed both in the overall population and in the subgroups. We calculated bias, limits of agreement (LA), and the percentage of error (PE) [20] . Bias was defined as the mean difference between BAP and NAP measurement, and 95% LA as the mean difference ±1.96 SD; the 95% limits are expected to include 95% of differences between the 2 measurement methods [21] .
The PE was defined as 1.96 SD of the bias over mean BP and it is calculated as:
Correlation and linear regression were used to describe the relationship between NAP and BAP.
Multiple regression analysis was used to predict the value of disagreement in MAP measurement between BAP and NAP based on the following variables: age, diabetes status, and hemodialysis vintage (length of time on dialysis). The same analysis was used to predict the value of disagreement in systolic BP measurement between BAP and NAP. Multiple correlation (R) and squared multiple correlation (R 2 ) were used to assess how the independent variables predicted the disagreement in systolic measurement. The F-ratio in ANOVA was used to calculate the statistical significance of the overall model.
Statistical analysis was performed using GraphPad version 6 (GraphPad Software Inc., San Diego, CA, USA) and SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).
Results
Study Population
Measurements were obtained with both devices in all patients.
Baseline characteristics of the study population are summarized in Table 1 .
The mean age of the patients was 68.9 ± 14.9 years with 65% of patients being older than 65 years and 30% older than 75 years. The mean time spent in hemodialysis was 49.1 ± 2.1 months. A majority of the patients (87.5%) had vascular calcifications at least in one aortic segment (aortic arch, thoracic and abdominal aorta). Eleven patients (27.5%) were diabetic with an average duration of disease of 17.2 ± 10.7 years; two of them underwent lower-extremity amputation for peripheral arterial disease. Three patients with diabetes (7.5%) were currently treated with oral anti-diabetic drugs and 8 (20%) with insulin therapy. Peripheral neuropathy was diagnosed in 6 cases (15%); only 2 of them were affected by diabetes. Correlation between diabetes and neuropathy was not statistically significant ( p = 0.8). 
Blood Pressure
The values of systolic, diastolic, and mean MAP were all normally distributed ( Fig. 1 ) . Table 2 shows the differences between the BAP and NAP measurements.
The mean of systolic, diastolic, and mean NAP were compared to mean systolic BAP (107 ± 19.7 vs. 122.3 ± 17.5 mm Hg, p ≤ 0.0001) to mean diastolic BAP (63.9 ± 12.14 vs. 62.9 ± 13 mm Hg, p = 0.54) and to mean BAP (78.7 ± 13.3 vs. 82.7 ± 13.2 mm Hg, p = 0.01), respectively.
Bland-Altman analysis ( Fig. 2 ; Table 2 ) comparing NAP measurements with BAP revealed the following outcome: a mean bias ± LA of 15.3 ± 34.8 mm Hg (29% error) for systolic BP, a mean bias ± LA of -0.9 ± 20.34 mm Hg (32% error) for diastolic BP, and a mean bias of 4.5 ± 21.34 mm Hg (26% error) for MAP. 11 (27.5) Insulin independent-diabetes, n (%) 3 (7.5) Insulin dependent-diabetes, n (%)
8 (20) Systolic, diastolic and mean arterial pressures are determined by the oscilloscopic method on the brachial artery. The data are averaged over 3 measurements.
AVF, arteriovenous fistula; BAP, brachial arterial pressure; BMI, body mass index; CVC, central venous catheter. Pearson correlation comparing NAP with brachial systolic, diastolic and MAP showed a correlation coefficient (R 2 ) of 0.33, 0.44, and 0.44, respectively, all statistically significant.
Subsequently, the same analysis was performed to evaluate the accuracy and precision of Nexfin in predicting MAP in 3 subgroups of patients selected for age, hemodialysis vintage, and diabetes status ( Table 3 ) .
Measurements in patients younger than 65 years and with a dialysis vintage of less than 12 months showed a better mean bias ± LA and a lower PE. Specifically, Nexfin measurements in non-diabetic subjects revealed a very good (R 2 = 0.79) and a highly significant ( p ≤ 0.0001) correlation with the oscillometric method, whereas recordings in diabetic subjects showed the worst bias ± LA (9.9 ± 36.02 mm Hg) with the highest 314 PE (45%). In diabetic patients, the measurements of MAP between the 2 devices showed a non-significant correlation ( p = 0.58).
Since the measurement of systolic NAP showed the highest grade of discrepancy when compared to BAP, we performed univariate and multivariate analyses to assess those variables that would have predicted the disagreement in these measurements. The multivariate analysis revealed that the variables diabetes, neuropathy, and systolic BAP were statistically significant (F (3.34) = 10.78, p < 0.005, R 2 = 0.488; Table 4 ). On the basis of this analysis, it is tempting to conclude that diabetes, systolic BAP, and neuropathy accounted for 29, 16, and 9% respectively of the variance of the discrepancies in recording systolic BP.
Discussion
In this study, we evaluated the ability of Nexfin to reconstruct BAP in 40 elderly hemodialysis patients with a high burden of comorbidities and an increased risk of vascular disease. To the best of our knowledge, this is the first report testing the device in a cohort of subjects on regular hemodialysis treatment.
Our findings showed that Nexfin, compared to the oscillometric method, had good accuracy but poor precision in the measurement of diastolic and mean BAP. On the other side, the device had the worst performance in measuring systolic BP; indeed, the resulting BP readings displayed substantial disagreements compared to the corresponding systolic BAP. Similar to our results, even Schattenkerk et al. [6] , in their work on Nexfin validation found the greatest discrepancy in the assessment of systolic BAP. However, differently from their findings, we found that the reconstruction of systolic BAP was less accurate and precise than that encountered in the validation study (15.3 ± 17.8 and -4.3 ± 8.7 mm Hg, respectively).
On the basis of our results, we suppose that Nexfin monitor does not meet the criteria of interchangeability with oscillometric sphygmomanometer in our hemodialysis patients. Two main reasons support this statement.
First, Nexfin underestimates systolic BAP values so extensively that the level of disagreement with oscillometric method is too wide for clinical application. Second, diastolic and mean BP measured peripherally have a too broad LA to be accepted in clinical setting. For instance, a MAP of 80 mm Hg would have the true measurement ranging from 59 to 101 mm Hg. A similar range of error must be regarded with care because it may mislead physicians in assessing the correct hemodynamic status of patients, leading consequently to inappropriate therapy.
In order to evaluate the reliability of cuff-finger technology in predicting tissue perfusion pressure [22] , we analyzed the disagreement of MAP in groups of patients selected for age, dialysis vintage, and diabetes status.
Patients older than 65 years, with dialysis vintage more than 12 months and with diabetes showed the most inaccurate and imprecise BP evaluation compared to their counterpart. Instead, detection of good correlation (R 2 = 0.79) between NAP and BAP, in patients without diabetes, increased a high level of suspicion for metabolic disease as cause of BP disagreements between the 2 devices.
On multivariate analysis, diabetes, neuropathy, and increase of systolic BAP were associated with worsening of discrepancies between systolic BAP and NAP. These 3 predictors raised concerns about the feasibility of Nexfin to perform a correct evaluation of BAP in the presence of vasculopathy, since diabetes [23, 24] and high systolic BAP [25] are prominent risk factors for atherosclerosis, and peripheral neuropathy may be expression of underlying microvascular disease [26] .
It is well-know that patients with end-stage renal disease have a high prevalence of vasculopathy [27, 28] ; several factors as uremia [29, 30] , diabetes [19, 20] , and hemodialysis treatment [31, 32] concur all together to the development of atherosclerotic lesions. Moreover, the vascular damage of patients with renal failure and with diabetes is aggravated by Monckeberg sclerosis, a noninflammatory calcification of tunica media [33] . Vascular calcification is a common finding in CKD, becoming almost a ubiquitous disease in dialysis patients [34] [35] [36] . According to the literature, we found calcification of the aorta in 87.5% of our subjects after a mean dialysis vintage of 49.1 ± 52.1 months.
Vascular calcification is believed to directly increase arterial stiffness. Of note, several studies have recently reported that calcification of the aorta is associated positively with arterial stiffening both in hemodialysis patients [37, 38] and in other cohorts [39] [40] [41] [42] [43] .
Based on these data, we suppose that high prevalence of calcifications in major vessel beds may interfere with the reliability of Nexfin technology in reconstructing BAP. Hence, we propose that arterial stiffening and consequent lack of arterial wall compliance might represent an important limiting factor for the working principle of the device, which relies on the volume clamp method described by Peñáz [10, 11] . It consists in determining the proper unloaded diameter of the finger arteries, namely a point at which transmural pressure across the finger arterial walls is zero by varying the pressure of the finger cuff inflatable bladder. In our opinion, failure to achievement of the unloaded state due to loss of arterial compliance, affects the accuracy of Nexfin technology negatively.
Additionally, peripheral arterial narrowing that may occur as a result of a diffuse and severe atherosclerotic process in patients with vascular calcification [44] [45] [46] may reduce blood flow distally [47] and may critically impair finger pressure measurement. Although, the Nexfin theoretically overcomes the problem reconstructing BAP through a population-based level correction formula [3] , we speculate that this model cannot be applied to chronic hemodialysis patients because of the enormous differences in clinical characteristics compared to the general population.
Nexfin is a promising and useful noninvasive continuous arterial BP monitor to determine key hemodynamic parameters during each hemodialysis session. The device has been widely tested in different groups of patients, but information on subjects on maintenance hemodialysis patients is lacking and there are few and conflicting data about the reliability of Nexfin in patients with diabetes [48, 49] . According to our own results the use of Nexfin deserves special attention in patients on maintenance hemodialysis with a high risk of vasculopathy. Therefore, further research with larger cohort of subjects is needed to validate the applicability of Nexfin in hemodialysis patients.
The principal limitation of this study is the lack of gold standard for BP measurement. The use of semi-automatic oscillometric device in the office setting is not likely to reflect true BP. Office BP reading, although is commonly performed in clinical practice, is characterized by a poor correlation to other modalities of BP monitoring as awake ambulatory BP (ABPM) and home BP [50] . The presence of physician or nurse might have contributed to the increase of patient anxiety and consequently might have triggered a falsely elevated BP in our patients.
Furthermore, recording of BP before starting HD has been reported to have a low correlation compared to interdialytic ABPM [51] . In particular, BP measurements obtained pre-HD shows low sensitivity and specificity compared to 24 and 48 h ABPM [52] .
Finally, semi-automatic oscillometric does not represent the gold standard for BP measurement that is still represented by the auscultatory technique using a mercury sphygmomanometer. However, BP readings provided by semi-automatic oscillometric instrument eliminated the observer's bias related with the use of the manual auscultatory technique [9, 15, 16, 53] .
Conclusions
In this study, we evaluated the accuracy and precision of Nexfin device, a continuous noninvasive arterial pressure monitoring system, in patients on maintenance hemodialysis. Nexfin monitor does not meet the absolute criteria for full interchangeability in this cohort of subjects when compared to the oscillometric method; Probably, the effect of advanced vasculopathy expressed by diabetes, neuropathy, and high systolic pressure may jeopardize the accuracy of the device. The discrepancies found in systemic BP reconstruction may lead to incorrect estimation of BP and consequently unnecessary therapeutic interventions. Further studies with large cohort of subjects are required to verify whether application of finger cuff technology in hemodialysis patients is able to monitor BP with a high level of agreement.
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